Estrella Immunopharma reported net income of -$2.31M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | ||||||||||||||||||||||
| Research & DevelopmentR&D | 2.61M | 5.21M | 7.88M | 0.48M | 0.08M | 0.03M | 3.55M | 6.38M | 2.90M | 1.41M | 4.66M | 4.15M | 0.03M | 1.40M | 1.40M | |||||||
| Selling, General & AdministrativeSG&A | 0.28M | 0.43M | 0.51M | 1.39M | 0.95M | 0.44M | 0.87M | 1.42M | 1.57M | 0.69M | 0.88M | 0.65M | 0.59M | 0.89M | 0.68M | |||||||
| Restructuring CostsRestructuring | 0.13M | 0.19M | 0.71M | 0.04M | 0.09M | 0.13M | 0.08M | 0.05M | 0.04M | 0.10M | 0.03M | 0.15M | 0.05M | |||||||||
| Other Operating ExpensesOther Opex | 0.01M | 0.16M | 0.12M | 0.40M | -0.13M | -0.19M | 0.29M | -0.71M | -0.04M | -0.09M | -0.13M | -0.12M | -0.05M | -0.04M | -0.10M | -0.03M | -0.15M | -0.05M | ||||
| Operating ExpensesOpex | 0.01M | 0.16M | 0.12M | 0.40M | 2.89M | 5.64M | 8.38M | 0.29M | 1.87M | 1.02M | 0.47M | 4.42M | 7.80M | 4.43M | 2.10M | 5.54M | 4.80M | 0.61M | 2.29M | 2.08M | ||
| Operating IncomeOp. Inc | -0.11M | -0.14M | -0.14M | -0.42M | -2.89M | -5.64M | -8.38M | -0.32M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | -0.65M | -2.30M | -2.08M | ||
| EBIT | -0.11M | -0.14M | -0.14M | -0.42M | -2.89M | -5.64M | -8.38M | -0.32M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | -0.65M | -2.30M | -2.08M | ||
| Non-operating items | ||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 567.00 | 857.00 | 0.00M | 0.06M | 0.20M | 0.38M | 0.11M | 0.22M | ||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 567.00 | 857.00 | 0.00M | |||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.22M | |||||||||||||||||||||
| Net income details | ||||||||||||||||||||||
| EBT | -0.11M | -0.14M | -0.14M | -0.36M | -0.34M | -5.64M | -8.38M | -0.10M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | -0.61M | -2.29M | -2.31M | ||
| Tax ProvisionsTaxes | 0.08M | 0.02M | 0.04M | 0.00M | 63.00 | 13.00 | 850.00 | -2.74M | ||||||||||||||
| Profit After TaxPAT | -0.11M | -0.14M | -0.14M | -0.36M | -2.89M | -5.64M | -8.38M | -0.14M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | -0.61M | -2.29M | -2.31M | ||
| Income from Continuing OperationsIncome (Continuing) | -0.11M | -0.14M | -0.14M | -0.36M | -0.34M | -5.72M | -8.40M | -0.14M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | 2.13M | -2.29M | -2.31M | ||
| Consolidated Net IncomeConsol Net Inc. | -0.11M | -0.14M | -0.14M | -0.36M | -0.34M | -5.72M | -8.40M | -0.14M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | 2.13M | -2.29M | -2.31M | ||
| Income towards Parent CompanyParent Net Inc | -0.11M | -0.14M | -0.14M | -0.36M | -0.34M | -5.72M | -8.40M | -0.14M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | 2.13M | -2.29M | -2.31M | ||
| Net Income towards Common StockholdersNet Income | -0.11M | -0.14M | -0.14M | -0.36M | -0.34M | -5.72M | -8.40M | -0.14M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | 2.13M | -2.29M | -2.31M | ||
| Additional items | ||||||||||||||||||||||
| EPS (Basic) | -0.01 | -0.03 | -0.01 | -0.03 | -0.24 | -0.57 | -5.92 | -0.04 | -1.78 | -0.03 | -0.01 | -0.12 | -0.22 | -0.12 | -0.06 | -0.15 | -0.13 | 0.06 | -0.05 | -0.05 | ||
| EPS (Diluted) | -0.01 | -0.03 | -0.01 | -0.03 | -0.03 | -0.57 | -2.59 | -0.10 | -1.78 | -0.03 | -0.01 | -0.12 | -0.22 | -0.12 | -0.06 | -0.15 | -0.13 | 0.06 | -0.05 | -0.05 | ||
| Shares Outstanding | 8.29M | 5.25M | 10.28M | 10.28M | 1.42M | 10.11M | 1.42M | 3.24M | 1.05M | 35.20M | 35.52M | 36.38M | 36.21M | 36.52M | 36.19M | 36.17M | 37.10M | 36.82M | 42.12M | 43.00M | ||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 8.29M | 5.25M | 10.28M | 10.28M | 10.28M | 10.11M | 3.24M | 1.42M | 1.05M | 35.20M | 35.59M | 36.38M | 36.21M | 36.52M | 36.19M | 36.17M | 37.10M | 36.82M | 42.12M | 43.00M | ||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 8.29M | 5.25M | 10.28M | 10.28M | 5.63M | 10.11M | 2.11M | 3.24M | 2.11M | 35.20M | 36.54M | 36.61M | 36.18M | 36.19M | 36.17M | 37.07M | 37.77M | 42.67M | 43.03M | 43.50M | ||
| EBITDA | -0.11M | -0.14M | -0.14M | -0.42M | -2.89M | -5.64M | -8.38M | -0.32M | -1.87M | -1.02M | -0.47M | -4.42M | -7.80M | -4.43M | -2.10M | -5.54M | -4.80M | -0.65M | -2.30M | -2.08M | ||
| Tax Rate | -1.43% | -0.23% | -41.04% | -0.02% | 0.00% | 0.00% | -0.02% | 447.49% |